[Full text] Recognizing Prognostic and Predictive Biomarkers in the Treatment of N | LCTT

Source : https://www.dovepress.com/recognizing-prognostic-and-predictive-biomarkers-in-the-treatment-of-n-peer-reviewed-fulltext-article-LCTT

PD-L1 testing is done through IHC with different assays utilized with various PD-1 or PD-L1 inhibitors; the mechanism of action of these inhibitors in relation to PD-L1 is well described. The 22C3 assay pairs with pembrolizumab, 28-8 assay with nivolumab, SP142 with atezolizumab, SP263 with durvalumab, and 73-10 with avelumab.